Remove 2007 Remove Clinical Trials Remove Data Remove Terpenes
article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

At the same time, the outlook on cannabis research data is largely positive. Research into the plant’s chemical compounds has also revealed a rich array of terpenes and flavonoids that may also account for the plant’s therapeutic effects (Kotsirilos and McGregor 2021 ). Data collection.

article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Israel’s Tikun Olam Making Moves in the U.S. and Canada

Freedom Leaf

Tikun Olam , which was founded in 2007, controls nearly 40% of the Israeli medical-marijuana market. We’re also continuing to do some other clinical trials in Israel, specifically with our strains.” Although it’s a little bit observational, we’re able to understand with empirical data what strains are assisting them.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).